Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

AKBA

0.00

Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it has been notified of eligibility to extend the expiration of a composition of matter patent covering Vafseo® (vadadustat). The new patent and 5-year extension eligibility strengthen Akebia's vadadustat intellectual property portfolio, which now includes 14 patents listed in the Orange Book with expiration dates out to 2036.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.